CONTRIBUTION TO LITERATURE: The CANVAS trial showed that canagliflozin was superior at preventing cardiovascular events.
DESCRIPTION: The goal of the trial was to evaluate the sodium-glucose cotransporter 2 inhibitor canagliflozin compared with placebo among patients with type 2 diabetes.
STUDY DESIGN: Randomized, Parallel, Placebo, Blinded. Patients with type 2 diabetes were randomized to canagliflozin (n = 5,795) versus placebo (n = 4,347). Patients in the canagliflozin arm received 300 mg daily or 100 mg daily.